Breaking News Instant updates and real-time market news.

NKTR

Nektar

$93.87

-7.57 (-7.46%)

, INCY

Incyte

$64.02

-19.05 (-22.93%)

07:36
04/09/18
04/09
07:36
04/09/18
07:36

Nektar data 'more robust' than Incyte's, says H.C. Wainwright

The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.

NKTR

Nektar

$93.87

-7.57 (-7.46%)

INCY

Incyte

$64.02

-19.05 (-22.93%)

MRK

Merck

$53.36

-1.17 (-2.15%)

BMY

Bristol-Myers

$60.88

-1.43 (-2.30%)

  • 09

    Apr

  • 14

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 26

    Apr

  • 01

    May

  • 03

    May

  • 08

    May

  • 12

    Jun

  • 10

    Jul

  • 23

    Oct

NKTR Nektar
$93.87

-7.57 (-7.46%)

04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.
04/02/18
HCWC
04/02/18
INITIATION
Target $125
HCWC
Buy
Nektar assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay assumed coverage of Nektar Therapeutics with a Buy rating and $125 price target. The stock has had a "stellar run, but activity in checkpoint refractory patients could be well received," Chattopadhyay tells investors in a research note. The analyst believes available data from NKTR-214 in combination with Opdivo points to "compelling clinical activity." He sees "significant upside to the stock" beyond what his $125 target suggests should the data hold up to scrutiny.
03/02/18
ADAM
03/02/18
NO CHANGE
Target $94
ADAM
Buy
Nektar price target raised to $94 from $80 at Canaccord
Canaccord Genuity analyst Arlinda Lee raised her price target for Nektar Therapeutics to $94 after the company reported Q4 results. Notable, Nektar provided a second update to Phase 1 Pivot-2 dose-escalation results indicating ongoing and further tumor shrinkage with improved and continuing response, Lee tells investors in a research note. Further, the company reported 60% response rate in 20 patients with PDL1-negative tumors at baseline, the analyst adds. She believes the update "further solidifies the central positioning" for wholly-owned drug candidate NKTR-214 in combination with anti-PD1. The analyst keeps a Buy rating on Nektar.
03/02/18
MZHO
03/02/18
NO CHANGE
Target $89
MZHO
Buy
Mizuho has increased conviction in Bristol possibly buying Nektar in 2018
Mizuho analyst Difei Yang believes there is a possibility for Bristol-Myers Squibb (BMY) to acquire Nektar Therapeutics (NKTR) in 2018. The analyst says new positive clinical data of NKTR-214 in combo with Bristol-Myers' Opdivo reinforces her conviction. Bristol-Myers "could make a move" prior to the readouts of Propel study, expected in the second half of 2018, where NKTR-214 was tested in combo with competing products, Tecentiq and Keytruda, Yang tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $89 price target following the company's Q4 results.
INCY Incyte
$64.02

-19.05 (-22.93%)

04/09/18
CANT
04/09/18
DOWNGRADE
Target $7
CANT
Neutral
Cantor downgrades NewLink with $7 target on added indoximod uncertainty
Cantor Fitzgerald analyst Mara Goldstein downgraded NewLink Genetics (NLNK) to Neutral from Overweight and cut her price target for the shares to $7 from $26. The analyst cites NewLink's decision to revisit the indoximod clinical program as the reason for the downgrade. Goldstein previously highlighted the differentiating factors between indoximod and Incyte's (INCY) epacadostat, but she now has reduced confidence given a "lack of decisive commentary" from NewLink management.
04/09/18
OPCO
04/09/18
NO CHANGE
Target $65
OPCO
Perform
Incyte price target lowered to $65 from $110 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte (INCY) to $65 from $110 following the update on the termination of ECHO-301 after epacadostat failed to show a PFS or OS benefit when combined with Merck's (MRK) Keytruda versus Keytruda alone. While the company plans to conduct subgroup analyses of ECHO-301 looking at various biomarkers such as PD-L1 expression and tumor mutational burden which may provide additional insights, the analyst sees no reason at this time to continue development of epacadostat as he considers it highly unlikely to demonstrate efficacy in other tumor types and/or combinations. Olson reiterates a Perform rating on Incyte's shares.
04/09/18
NOMU
04/09/18
NO CHANGE
Target $102
NOMU
Buy
Incyte price target lowered to $102 from $139 at Nomura Instinet
Nomura Instinet analyst Christopher Marai on Friday lowered his price target for Incyte to $102 after the Phase ECHO-301 trial of epacadostat and pembrolizumab in advanced metastatic melanoma was stopped. The analyst keeps a Buy rating on the shares. He tells investors to focus on the company's TKI pipeline.
04/09/18
RHCO
04/09/18
DOWNGRADE
Target $5
RHCO
Hold
NewLink Genetics downgraded to Hold at SunTrust on Incyte trial failure
As reported late last week, SunTrust analyst Peter Lawson downgraded NewLink Genetics (NLNK) to Hold from Buy and lowered his price target to $5 from $19. Lawson cites the announcement of negative results from the Phase 3 ECHO-301 of epacadostat + Keytruda in melanoma by Incyte (INCY), saying the data also implies a "significant negative read through for NewLink's IDO agent, indoximod". Lawson adds that the results have led him to remove melanoma from his NewLink model and also reduce the probability of success in pancreatic cancer, lowering the probability of adjusted peak sales from $415M to just $11M.
MRK Merck
$53.36

-1.17 (-2.15%)

04/06/18
CANT
04/06/18
NO CHANGE
Target $26
CANT
Overweight
Cantor says premature to assume NewLink trial will fail like Incyte's
NewLink Genetics' (NLNK) indoximod, which acts as a tryptophan mimetic rather than an IDO enzymatic inhibitor, has shown differentiated data versus Incyte's (INCY) epacadostat, Cantor Fitzgerald analyst Mara Goldstein tells investors in a research note. NewLink is trading down 37.5%, or $2.75, to $4.57 after Incyte announced that its ECHO-301 study of epacadostat plus Merck's (MRK) Keytruda versus Keytruda alone was unsuccessful in treating advanced melanoma. Goldstein thinks assuming failure of indoximod "may be premature," but she acknowledges that NewLink shares are likely to be pressured with the company's Phase III trial end likely over a year away. If indoximod is truly differentiated, however, NewLink shares will be higher than $26 given the "now likely limited competition," Goldstein contends. She reiterates an Overweight rating on the shares with a $26 price target.
04/09/18
JEFF
04/09/18
DOWNGRADE
Target $4
JEFF
Hold
NewLink Genetics downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin late Friday downgraded NewLink Genetics (NLNK) to Hold from Buy and cut his price target for the shares to $4 from $17. The stock closed Friday down 43%, or $3.12, to $4.20. The analyst does not see a scenario in which the company's IDO inhibitor can avoid the same fate as Incyte and Merck's epacadostat plus Keytruda failed study.
BMY Bristol-Myers
$60.88

-1.43 (-2.30%)

03/20/18
JPMS
03/20/18
NO CHANGE
Target $75
JPMS
Overweight
Bristol-Myers price target raised to $75 from $70 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Bristol-Myers Squibb to $75 saying the company's opportunity in non-lung tumor types is broad and underappreciated. The analyst sees a number of $1B-plus indications for Opdivo beyond non-small-cell lung carcinoma, including kidney, liver, gastric, small cell lung and melanoma. These indications should represent the majority of Opdivo sales over time, Schott tells investors in a research note. The analyst keeps an Overweight rating on Bristol-Myers.
03/12/18
LEER
03/12/18
UPGRADE
Target $66
LEER
Outperform
Leerink upgrades Merck to Outperform ahead of KN-189 presentation
Leerink analyst Seamus Fernandez upgraded Merck (MRK) to Outperform from Market Perform with an unchanged price target of $66. The shares closed Friday up 38c to $55.14. Keytruda will continue to dominate the first-line non-small cell lung cancer market, Fernandez tells investors in a research note. Following his firm's lung cancer survey, the analyst believes Merck will deliver upside to consensus Keytruda estimates along with positive earnings leverage in the second half of 2018 and 2019. He thinks KN-189 likely will show a clinically meaningful overall survival benefit for the Keytruda plus chemo combo in all patients, including a strong benefit in patients with moderate or low PD-L1 biomarker levels. Fernandez does not believe Bristol-Myers' (BMY) Opdivo and Yervoy combo will supplant Keytruda as the market leader. The analyst thinks now is the time to own shares of Merck.

TODAY'S FREE FLY STORIES

CNMD

CONMED

$63.14

1.36 (2.20%)

21:15
04/25/18
04/25
21:15
04/25/18
21:15
Recommendations
CONMED analyst commentary at Piper Jaffray »

CONMED price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 23

    May

SSNLF

Samsung

20:48
04/25/18
04/25
20:48
04/25/18
20:48
Hot Stocks
Samsung sees Q2 DRAM demand to stay solid and NAND demand to strengthen »

Sees Q2 demand for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

AXS

Axis Capital

$56.82

-0.255 (-0.45%)

20:34
04/25/18
04/25
20:34
04/25/18
20:34
Earnings
Axis Capital reports Q1 adjusted EPS $1.46, consensus $1.16 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

VERI

Veritone

$16.92

-0.18 (-1.05%)

20:31
04/25/18
04/25
20:31
04/25/18
20:31
Hot Stocks
Veritone to integrate BrainChip Holding AI machine learning applications »

BrainChip Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 29

    May

ENB

Enbridge

$29.27

-0.13 (-0.44%)

, EEP

Enbridge Energy

$10.55

0.29 (2.83%)

20:28
04/25/18
04/25
20:28
04/25/18
20:28
Hot Stocks
Enbridge completes assessment of judge recommendations on Line 3 replacement »

After review of the…

ENB

Enbridge

$29.27

-0.13 (-0.44%)

EEP

Enbridge Energy

$10.55

0.29 (2.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 10

    May

  • 10

    May

PEP

PepsiCo

$101.11

-0.32 (-0.32%)

, ABBV

AbbVie

$91.91

0.57 (0.62%)

20:25
04/25/18
04/25
20:25
04/25/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PEP

PepsiCo

$101.11

-0.32 (-0.32%)

ABBV

AbbVie

$91.91

0.57 (0.62%)

UNP

Union Pacific

$136.11

3.3 (2.48%)

UPS

UPS

$108.54

0.34 (0.31%)

BMY

Bristol-Myers

$51.78

0.2 (0.39%)

COP

ConocoPhillips

$65.07

-0.24 (-0.37%)

TWX

Time Warner

$96.27

0.25 (0.26%)

RTN

Raytheon

$213.25

-5.5 (-2.51%)

CME

CME Group

$161.07

-0.52 (-0.32%)

GM

General Motors

$38.10

0.18 (0.47%)

ITW

Illinois Tool Works

$151.68

2.1 (1.40%)

SPGI

S&P Global

$189.68

0.62 (0.33%)

VLO

Valero

$108.68

0.37 (0.34%)

PX

Praxair

$149.84

3.05 (2.08%)

LUV

Southwest

$53.85

-0.03 (-0.06%)

HLT

Hilton

$81.85

-0.19 (-0.23%)

RCL

Royal Caribbean

$118.49

1.2 (1.02%)

ALXN

Alexion

$106.07

-0.37 (-0.35%)

IP

International Paper

$53.44

0.68 (1.29%)

MGM

MGM Resorts

$35.32

-0.2 (-0.56%)

HSY

Hershey

$93.51

0.7 (0.75%)

DHI

D.R. Horton

$44.94

1.195 (2.73%)

NLSN

Nielsen

$34.34

0.835 (2.49%)

DPZ

Domino's Pizza

$233.00

0.925 (0.40%)

TSCO

Tractor Supply

$62.21

1 (1.63%)

DNKN

Dunkin' Brands

$62.13

0.92 (1.50%)

CRI

Carter's

$104.96

0.95 (0.91%)

TREE

LendingTree

$307.20

-20.45 (-6.24%)

SAVE

Spirit Airlines

$37.64

-0.615 (-1.61%)

KBR

KBR

$16.02

-0.255 (-1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 07

    May

  • 08

    May

  • 10

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 24

    May

  • 24

    May

  • 30

    May

  • 05

    Jun

  • 12

    Jun

  • 14

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 10

    Jul

ROK

Rockwell Automation

$167.30

5.335 (3.29%)

20:08
04/25/18
04/25
20:08
04/25/18
20:08
Downgrade
Rockwell Automation rating change at Vertical Research »

Rockwell Automation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SNDE

Sundance Energy

$4.53

-0.03 (-0.66%)

, PXD

Pioneer Natural

$198.97

2.96 (1.51%)

20:02
04/25/18
04/25
20:02
04/25/18
20:02
Hot Stocks
Sundance Energy Australia acquires Eagle Ford assets, announces equity raise »

Sundance Energy Australia…

SNDE

Sundance Energy

$4.53

-0.03 (-0.66%)

PXD

Pioneer Natural

$198.97

2.96 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

  • 22

    May

SSNLF

Samsung

19:51
04/25/18
04/25
19:51
04/25/18
19:51
Earnings
Samsung reports Q1 net profit KRW 11.61T »

Compares to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CHKP

Check Point

$96.33

-6.62 (-6.43%)

19:42
04/25/18
04/25
19:42
04/25/18
19:42
Recommendations
Check Point analyst commentary at Jefferies »

Check Point price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

QTS

QTS Realty Trust

$34.04

0.31 (0.92%)

19:35
04/25/18
04/25
19:35
04/25/18
19:35
Recommendations
QTS Realty Trust analyst commentary at MUFG »

QTS Realty Trust price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 03

    May

STB

Student Transportation

19:23
04/25/18
04/25
19:23
04/25/18
19:23
Hot Stocks
Student Transportation obtains court order approving Spinner Can Acquireco deal »

Student Transportation is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCMGY

Newcrest Mining

19:15
04/25/18
04/25
19:15
04/25/18
19:15
Hot Stocks
Newcrest Mining reports Q3 gold production 576K oz, down 6% from last quarter »

Reports Q3 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSA

Public Storage

$193.62

-0.115 (-0.06%)

19:04
04/25/18
04/25
19:04
04/25/18
19:04
Hot Stocks
Public Storage names Natalia Johnson chief HR officer »

Ronald L. Havner, Jr.,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

CADE

Cadence Bancorp

$28.80

-0.14 (-0.48%)

19:03
04/25/18
04/25
19:03
04/25/18
19:03
Earnings
Cadence Bancorp reports Q1 EPS 46c, consensus 44c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 14

    May

  • 24

    Sep

USAK

USA Truck

$25.56

-0.84 (-3.18%)

19:02
04/25/18
04/25
19:02
04/25/18
19:02
Hot Stocks
USA Truck names Tim Guin as EVP and Chief Commercial Officer »

USA Truck announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

BCS

Barclays

$12.01

-0.085 (-0.70%)

, PYPL

PayPal

$74.00

-1.29 (-1.71%)

19:01
04/25/18
04/25
19:01
04/25/18
19:01
Hot Stocks
Barclays, PayPal announces strategic partnership »

Barclays (BCS) announced…

BCS

Barclays

$12.01

-0.085 (-0.70%)

PYPL

PayPal

$74.00

-1.29 (-1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 22

    May

  • 23

    May

  • 12

    Jun

ORLY

O'Reilly Automotive

$228.03

3.31 (1.47%)

, CMG

Chipotle

$339.30

6.4 (1.92%)

19:00
04/25/18
04/25
19:00
04/25/18
19:00
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

ORLY

O'Reilly Automotive

$228.03

3.31 (1.47%)

CMG

Chipotle

$339.30

6.4 (1.92%)

PCMI

PCM, Inc.

$10.60

0.1 (0.95%)

AMD

AMD

$9.72

-0.37 (-3.67%)

FB

Facebook

$159.69

0.03 (0.02%)

ECHO

Echo Global

$27.80

0.15 (0.54%)

XLNX

Xilinx

$63.70

-0.34 (-0.53%)

PYPL

PayPal

$74.00

-1.29 (-1.71%)

ALGN

Align Technology

$245.24

5.72 (2.39%)

CTXS

Citrix

$96.54

0.04 (0.04%)

V

Visa

$121.00

-0.41 (-0.34%)

CLGX

CoreLogic

$43.85

-0.57 (-1.28%)

F

Ford

$11.11

0.16 (1.46%)

QCOM

Qualcomm

$49.77

-0.17 (-0.34%)

LVS

Las Vegas Sands

$72.42

-1.38 (-1.87%)

LM

Legg Mason

$37.64

0.25 (0.67%)

INTU

Intuit

$176.38

-2.25 (-1.26%)

TWTR

Twitter

$29.88

-0.6 (-1.97%)

FARO

FARO Technologies

$60.50

-1.85 (-2.97%)

LMAT

LeMaitre

$39.00

0.19 (0.49%)

UHS

Universal Health

$122.03

1.5 (1.24%)

EBAY

eBay

$40.98

-0.2 (-0.49%)

T

AT&T

$35.19

0.19 (0.54%)

KEX

Kirby

$82.95

-1.85 (-2.18%)

GG

Goldcorp

$13.97

-0.38 (-2.65%)

BMRN

BioMarin

$81.41

0.33 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 02

    May

  • 02

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 25

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 27

    Jul

  • 12

    Sep

NBIX

Neurocrine

$78.13

-0.3 (-0.38%)

18:59
04/25/18
04/25
18:59
04/25/18
18:59
Hot Stocks
Neurocrine says Ingrezza improved TD symptoms regardless of body region »

Neurocrine Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

AZPN

Aspen Technology

$85.50

0.39 (0.46%)

18:54
04/25/18
04/25
18:54
04/25/18
18:54
Earnings
Aspen Technology raises FY18 adj. EPS view to $2.24-$2.27 from $2.16-$2.21 »

Consensus $2.21. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 12

    Jun

AZPN

Aspen Technology

$85.50

0.39 (0.46%)

18:53
04/25/18
04/25
18:53
04/25/18
18:53
Earnings
Aspen Technology sees Q4 adjusted EPS 53c-55c, consensus 57c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 12

    Jun

ESV

Ensco

$6.03

-0.15 (-2.43%)

18:52
04/25/18
04/25
18:52
04/25/18
18:52
Earnings
Ensco reports Q1 adjusted EPS (32c), consensus (27c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CLB

Core Laboratories

$120.25

2.07 (1.75%)

18:50
04/25/18
04/25
18:50
04/25/18
18:50
Earnings
Core Laboratories sees Q2 EPS 64c-66c, consensus 66c »

Expects Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 01

    May

  • 01

    May

  • 07

    May

SPY

SPDR S&P 500 ETF Trust

$263.64

0.52 (0.20%)

, SPX

S&P 500

18:47
04/25/18
04/25
18:47
04/25/18
18:47
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

France's Macron sees…

SPY

SPDR S&P 500 ETF Trust

$263.64

0.52 (0.20%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

18:41
04/25/18
04/25
18:41
04/25/18
18:41
Periodicals
Breaking Periodicals news story on Samsung »

Samsung to sell Hanwha…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.